The UK is witnessing a noticeable surge in interest surrounding entheogenic substances. Beyond the familiar use of psilocybin and LSD, scientists and enthusiasts are increasingly focused on less-charted areas, particularly the copyright compound and the budding cannabinoid, cannabigerol. This expanding community encompasses therapeutic research int